{"id":4097,"date":"2026-11-02T09:00:00","date_gmt":"2026-11-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4097"},"modified":"2026-11-05T20:35:28","modified_gmt":"2026-11-06T00:35:28","slug":"syndax-names-aaron-ondrey-to-succeed-retiring-cfo","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4097","title":{"rendered":"Syndax Names Aaron Ondrey to Succeed Retiring CFO"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Syndax Pharmaceuticals<\/p>\n

Event Type<\/strong><\/p>\n

CFO transition<\/p>\n

Modality<\/strong><\/p>\n

Not applicable (corporate)<\/p>\n

Asset<\/strong><\/p>\n

Revumenib; axatilimab<\/p>\n

Target<\/strong><\/p>\n

Menin; CSF1R<\/p>\n

Disease Area<\/strong><\/p>\n

Acute leukemia; chronic GVHD<\/p>\n

Summary<\/h4>\n

Previously missed November 2 leadership change: Syndax appointed Aaron A. Ondrey chief financial officer effective November 9, succeeding Keith A. Goldan, who decided to retire from the CFO role. The transition occurs as Syndax commercializes revumenib and axatilimab; motive beyond Goldan\u2019s stated retirement was not disclosed.<\/p>\n

The company and SEC filing identify Ondrey as former CFO of Beren Therapeutics and Mirati Therapeutics, with earlier transaction experience at Arena Pharmaceuticals. Goldan has served as Syndax CFO since 2022. The company did not disclose Goldan\u2019s next destination or a continuing advisory or board position.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation A:<\/strong> Ondrey\u2019s finance and transaction background may support capital planning and commercialization scale-up. His prior CFO roles and the timing of Syndax\u2019s product launches support this as an execution hypothesis. Counterargument: background and timing alone do not establish a financing, deal or commercial pivot.<\/p>\n

Interpretation B:<\/strong> this is a planned succession with limited near-term strategic impact. The disclosed retirement and named successor support continuity, while transition quality remains unknown. Subsequent guidance accuracy, disclosure quality, cash conversion, financing decisions and leadership retention will test the effect.<\/p>\n

Company and Product Background<\/h4>\n

Syndax markets revumenib, a menin inhibitor for genetically defined acute leukemias, and develops or commercializes axatilimab, an anti-CSF1R antibody for chronic graft-versus-host disease. The CFO oversees financial reporting and capital allocation across these programs.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The effective date is November 9; the announcement and filing were November 2.<\/li>\n
  • Reason disclosed: Goldan\u2019s decision to retire from the CFO role.<\/li>\n
  • Next destination and continuing role undisclosed.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    A material finance-leadership transition at a commercial-stage hematology company. There is no evidence yet that it changes Syndax\u2019s strategy or execution quality.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: neutral. Confidence in Facts: high for the company and SEC disclosures. Confidence in Interpretation: low because effects on operations are unobserved.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Previously missed November 2 leadership change: Syndax appointed Aaron A. Ondrey chief financial officer effective November 9, succeeding Keith A. Goldan, who decided to retire from the CFO role. The transition occurs as Syndax…<\/p>\n","protected":false},"author":1,"featured_media":4104,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[196],"tags":[1386,1385,75],"class_list":["post-4097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-leadership-tracker","tag-axatilimab","tag-revumenib","tag-syndax-pharmaceuticals"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4097"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4097\/revisions"}],"predecessor-version":[{"id":4119,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4097\/revisions\/4119"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4104"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}